Supplementary Figure 2A. Supplementary Figure 2A. Analysis by HIC of Trastuzumab based antibody-drug conjugates (ADCs) with varying Drug-to-Antibody Ratios (DARs) and payloads. Supplementary Figure 2B. Analysis of Disitamab based antibody-drug conjugates (ADCs) with varying Drug-to-Antibody Ratios (DAR) and payload types by HIC.